EGFR and colorectal carcinoma: We found that the SMARCA4R1157W mutant increased the binding access to PRMT1-mediated H4R3me2a and enhanced ATPase activity and chromatin remodeling activities, thereby reinforcing EGFR and TNS4 expression and accelerating the progression of CRC.